4/A: Adaptive Bio Officer Exercises Options, Sells Shares

Adaptive Biotechnologies' Chief People Officer, Francis Lo, exercised stock options and subsequently sold a portion of the acquired common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Francis Lo, Chief People Officer of Adaptive Biotechnologies Corp (ADPT), reported transactions involving the exercise of stock options and the sale of common stock.
• On December 22, 2025, Lo acquired a total of 4,394 shares of common stock through the exercise of stock options at various prices: 1,100 shares at $7.80, 1,100 shares at $8.46, and 2,194 shares at $3.99.
• Concurrently, Lo disposed of 4,394 shares of common stock at a weighted-average price of $17.50, with individual sales ranging from $17.49 to $17.50.
• All reported transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by Lo on September 15, 2025.
• Following these transactions, Lo directly beneficially owns 315,978 shares of common stock and indirectly owns 2,500 shares through a spouse (You Jin Lee).

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction involving the exercise of stock options and subsequent sale of shares under a pre-arranged 10b5-1 plan. This is a common practice for executive compensation management and does not inherently indicate a positive or negative shift in the company's fundamental outlook.

Positives

• The exercise of stock options indicates the officer is realizing value from their equity compensation.
• The sale price of $17.50 per share is significantly higher than the exercise prices ($7.80, $8.46, $3.99), indicating a profitable transaction for the officer.

Negatives

• The sale of shares by a Chief People Officer, even under a 10b5-1 plan, could be perceived by some investors as a lack of confidence, though it is a common practice for executive compensation management.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

Insider transactions, such as the exercise of stock options and subsequent sale of shares, are a routine part of executive compensation and personal financial planning within the biotechnology industry and across publicly traded companies. The use of a Rule 10b5-1 plan indicates a pre-scheduled transaction, which is a common practice to avoid accusations of trading on material non-public information.

Related Party Transactions

• Francis Lo indirectly beneficially owns 2,500 shares of common stock through his spouse, You Jin Lee.

Stakeholder Impact

• Shareholders: Minimal direct impact, as this is a routine insider transaction under a pre-arranged plan. It does not signal a change in company strategy or financial health.
• Employees: No direct impact mentioned.

Key Dates

Recommendation

The filing details a routine insider transaction where an officer exercised stock options and sold a portion of the shares under a pre-arranged 10b5-1 plan. This type of transaction is common for executive compensation management and does not typically indicate a significant change in the company's fundamental outlook or warrant an immediate change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this filing alone does not provide new information to alter an existing investment thesis.

Keywords

Adaptive Biotechnologies, ADPT, Insider Transaction, Form 4, Stock Options, Share Sale, 10b5-1 Plan, Chief People Officer, Francis Lo